Table 3 Encounter-level data on the explorative process outcomes including accurate documentation of risk assessment and clinicians’ recommended surveillance intervals by risk group. N refers to the number of encounters evaluated in each risk group and phase

Low Risk

Pre-implementation (N = 60)

Integration (N = 54)

Evaluation (N = 54)

Accurate Documentation

19 [31.7%]

25 [46.3%]

45 [83.3%]

Recommendation for guideline-concordant surveillance interval

39 [65.0%]

37 [68.5%]

38 [70.4%]

Intermediate Risk

Pre-implementation (N = 72)

Integration (N = 72)

Evaluation (N = 101)

Accurate Documentation

41 [56.9%]

40 [55.6%]

63 [62.4%]

Recommendation for guideline-concordant surveillance interval

66 [91.7%]

67 [93.1%]

95 [94.1%]

High Risk

Pre-implementation (N = 116)

Integration (N = 87)

Evaluation (N = 139)

Accurate Documentation

85 [73.3%]

64 [73.6%]

116 [83.5%]

Recommendation for guideline-concordant surveillance interval

110 [94.8%]

80 [92.0%]

128 [92.1%]

Overall (combining all risk levels)

Pre-implementation (N = 248)

Integration (N = 213)

Evaluation (N = 294)

Accurate Documentation

145 [58.4%]

129 [60.5%]

224 [76.2%]

Recommendation for guideline-concordant surveillance interval

215 [86.6%]

184 [86.3%]

261 [88.7%]